<p>(A) Quantitative FLIM-FRET data shown as percent efficiency of FRET for the mCerulean-TG2-eYFP FRET sensor after a 16 hour treatment with either the irreversible TG2 inhibitor, NC9, or the reversible TG2 inhibitor, CP4d. (B) Percent efficiency of FRET graph generated following treatment of TG2 sensor with 5 increasing concentrations of CP4d. (C) Percent efficiency of FRET graph for TG2 sensor following treatment with 10 µM NC9 for 5 different time points from 0 to 24 hours. Black line represents median values, boxes encompass 25% and 75% confidence intervals and whiskers indicate the 5% to 95% confidence intervals. *p<0.001, **p<0.05 and N.S = not significant. N>10 for 4 replicates.</p
<p>A–B. TR-FRET values obtained at RT (A) or 4°C (B) using 2B7-Tb (1 ng/µl) - MW1-d2 (10 ng/µl) on d...
<p>AI-2 concentration curves for the two recombinant proteins as a function of time and measured by ...
<p>The upper graph shows the percent activity of 3CLpro of FIPV, SARS-CoV, and MERS-CoV in the prese...
<p>(A) Quantitative FLIM-FRET data shown as percent efficiency of FRET for the mCerulean-TG2-eYFP FR...
Transglutaminase type 2 (TG2) is a ubiquitously expressed member of the transglutaminase family, cap...
Transglutaminase type 2 (TG2) is a ubiquitously expressed member of the transglutaminase family, cap...
<p>Throughout this figure the donor involved is denoted by the shape of the point (EGFP = circle, Cl...
<p>a) The glucose biosensor has maximum FRET efficiency in the absence of ligand. The binding of glu...
<div><p>Mentioned are construct details (column 1–3), unique Lab ID (column 4), % ratio change (expr...
<p>A) and B) Modeling analysis of the pS24n response to increasing concentrations of TGF-β (A) and d...
<p>The control is NowGFP-mRuby2 FRET pair without thrombin cleavage site (LVPS instead of LVPR). ΔR/...
<p>(<b>A</b>) <b>The effect of TG inhibitors on R37 and KP1 cells using the XTT assay.</b> R37 and K...
<p>Representative calibrations of each sensor localized to the nucleus. The background corrected FRE...
<p>(<b>A</b>) Inhibition by Mg·AMP with Mg·ADP as variable substrate. Measurements were assayed at f...
<p>(A) Images show the lifetime maps of FRET across cells using a pseudocolour scale (blue, normal G...
<p>A–B. TR-FRET values obtained at RT (A) or 4°C (B) using 2B7-Tb (1 ng/µl) - MW1-d2 (10 ng/µl) on d...
<p>AI-2 concentration curves for the two recombinant proteins as a function of time and measured by ...
<p>The upper graph shows the percent activity of 3CLpro of FIPV, SARS-CoV, and MERS-CoV in the prese...
<p>(A) Quantitative FLIM-FRET data shown as percent efficiency of FRET for the mCerulean-TG2-eYFP FR...
Transglutaminase type 2 (TG2) is a ubiquitously expressed member of the transglutaminase family, cap...
Transglutaminase type 2 (TG2) is a ubiquitously expressed member of the transglutaminase family, cap...
<p>Throughout this figure the donor involved is denoted by the shape of the point (EGFP = circle, Cl...
<p>a) The glucose biosensor has maximum FRET efficiency in the absence of ligand. The binding of glu...
<div><p>Mentioned are construct details (column 1–3), unique Lab ID (column 4), % ratio change (expr...
<p>A) and B) Modeling analysis of the pS24n response to increasing concentrations of TGF-β (A) and d...
<p>The control is NowGFP-mRuby2 FRET pair without thrombin cleavage site (LVPS instead of LVPR). ΔR/...
<p>(<b>A</b>) <b>The effect of TG inhibitors on R37 and KP1 cells using the XTT assay.</b> R37 and K...
<p>Representative calibrations of each sensor localized to the nucleus. The background corrected FRE...
<p>(<b>A</b>) Inhibition by Mg·AMP with Mg·ADP as variable substrate. Measurements were assayed at f...
<p>(A) Images show the lifetime maps of FRET across cells using a pseudocolour scale (blue, normal G...
<p>A–B. TR-FRET values obtained at RT (A) or 4°C (B) using 2B7-Tb (1 ng/µl) - MW1-d2 (10 ng/µl) on d...
<p>AI-2 concentration curves for the two recombinant proteins as a function of time and measured by ...
<p>The upper graph shows the percent activity of 3CLpro of FIPV, SARS-CoV, and MERS-CoV in the prese...